

Evonik now offers enteric protected ready-to-fill capsules – EUDRACAP® – in IPEC-GMP quality

12 July 2022

- EUDRACAP® functional, ready-to-fill capsules now available for human clinical trials
- Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
- Expands System Solutions based on technology platform for oral advanced drug delivery

Main press contact

Julia Born
Head of Market Communications
Health Care
Phone +49 6151184984
julia1.born@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Essen, Germany. Evonik's EUDRACAP® enteric easy-to-handle capsules are now globally available produced under IPEC-GMP. Launched last year, EUDRACAP® enteric are functional, ready-to-fill capsules that help pharmaceutical companies bring complex oral drug products to market faster. By offering a capsule that already provides the desired protection, companies no longer need to invest time in complex formulation development and can accelerate their drug development programs. EUDRACAP® builds on Evonik's unique expertise in advanced drug delivery and belongs to the company's set of System Solutions. These are multi-component offerings across products, technologies and services that provide customers with end-to-end development and manufacturing services for complex drug products.

"We were thrilled at the market response to EUDRACAP® enteric when it launched last year. By offering our platform produced under IPEC-GMP, our customers can test their oral drug products in a clinical setting and move a step closer to commercialization," says Dr. Axel Schröder head of Global Business Segment Oral Drug Delivery Solutions at Evonik Health Care.

Oral drugs are being developed rapidly and there is new emphasis on those using mRNA or targeting the microbiome. "We are happy to provide our unique EUDRACAP® solution to meet the needs of customers with a growing number of sensitive molecules in their drug product portfolio," says Dr. Bettina Hölzer, senior project manager Strategic Marketing Oral Drug Delivery Solutions at Evonik Health Care.

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

EUDRACAP® leverages Evonik's established EUDRAGIT® functional coatings to optimize the release profile of oral drug products. The coated HPMC (hydroxypropyl methyl cellulose) capsules are particularly suited to protect sensitive active pharmaceutical ingredients from moisture and gastric acid and as an added benefit, EUDRACAP® enteric runs smoothly on fully automated machines at full speed.

In addition to EUDRACAP® enteric, the EUDRACAP® Select line provides tailor-made CDMO (Contract Development and Manufacturing Organization) services to meet specific customer requirements, including a range of sizes, colors, and customized release profiles.

The launch of EUDRACAP® enteric produced under IPEC-GMP follows a series of product and technology innovations launched by the Health Care business of Evonik over the past few years. In 2020, Evonik launched EUDRATEC® Fasteric, an advanced oral drug delivery technology that provides enteric protection and effective targeting of the upper small intestine which was followed earlier this year by the launch of EUDRATEC® SoluFlow, a solubility enhancement process technology.

Evonik Health Care is one of the world's leading CDMOs for complex oral and parenteral drug products that require advanced delivery solutions. It is also one of the world's largest suppliers of cell culture ingredients, medical device excipients and a leading global CDMO for APIs, HPAPIs and intermediates.

As part of Evonik's life sciences division, Nutrition & Care, Evonik Health Care plays a key role in fulfilling the division's goal to increase its share of System Solutions from 20 percent today to more than 50 percent by 2030.

More Information

<https://healthcare.evonik.com/en/pharmaceuticals/oral-drug-delivery/oral-excipients/eudracap-portfolio>

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.